Tscan Therapeutics Intrinsic Value Calculator – TScan Therapeutics Anticipates Significant Value from 2024 TCR-T Data Readouts

☀️Trending News

TSCAN ($NASDAQ:TCRX) Therapeutics is a biopharmaceutical company that focuses on developing immunotherapies to treat cancer and other serious diseases. The company is anticipating the significant value that could come from two 2024 TCR-T data readouts, which have the potential to revolutionize the industry if utilized properly. The TCR-T data readouts are based on a novel approach to target and reprogram healthy T-cells. This technology has the potential to offer superior efficacy and safety compared to other therapies currently available.

Additionally, TSCAN believes that the data readouts could potentially bring substantial value, both for the company and the industry as a whole. The two 2024 TCR-T data readouts that TSCAN is anticipating are a Phase 1 study of its lead product candidate, TS-1, and a Phase 2/3 study of its second product candidate, TS-2. TSCAN believes that the successful completion of these studies could bring significant value to the company in terms of potential revenues and cost savings. It is also anticipated that the successful completion of these studies could potentially result in increased market capitalization for the company. Overall, TSCAN Therapeutics is expecting significant value from its two 2024 TCR-T Data Readouts if utilized properly. The company is hopeful that these studies will yield positive results for both the company and the industry as a whole, allowing them to continue to make strides in the field of cancer research and treatment.

Share Price

Thursday saw TSCAN THERAPEUTICS close at $6.0, a 0.8% drop from its prior closing price of $6.0. Despite this minor dip in stock price, the company is anticipating significant value from their upcoming 2024 TCR-T Data Readouts. TSCAN THERAPEUTICS is currently working on developing novel cancer treatments and immunotherapies using its proprietary technology platform. These readouts may prove to be a major boost for the company’s efforts, setting them up for long-term success in the healthcare industry. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Tscan Therapeutics. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Tscan Therapeutics. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Tscan Therapeutics. More…

Key Ratios Snapshot

Some of the financial key ratios for Tscan Therapeutics are shown below. More…

Analysis – Tscan Therapeutics Intrinsic Value Calculator

GoodWhale has conducted an analysis of TSCAN THERAPEUTICS‘s wellbeing and are pleased to present our findings. After taking into account the company’s financials, industry trends, and other factors, our proprietary Valuation Line indicates that the fair value of TSCAN THERAPEUTICS share is around $3.2. However, we observe that TSCAN THERAPEUTICS stock is currently traded at $6.0, indicating an overvaluation of 89.4%. More…

Peers

TScan Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of its proprietary T cell receptor scanning technology for the treatment of cancer and autoimmune diseases. The company’s primary competitors are Freeline Therapeutics Holdings PLC, PhaseBio Pharmaceuticals Inc, and Werewolf Therapeutics Inc.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a biopharmaceutical company that focuses on the development and commercialization of gene therapies for chronic liver diseases. The company has a market cap of $42.89 million and a return on equity of -1.18%. Freeline’s lead product candidate, FLT180a, is in clinical development for the treatment of hemophilia B and other bleeding disorders. The company is also developing FLT190 for the treatment of Wilson disease.

– PhaseBio Pharmaceuticals Inc ($NASDAQ:PHAS)

Bio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer. The company’s lead product candidate is BIO-1402, a small molecule inhibitor of the PI3K/mTOR pathway. The company’s second product candidate is BIO-1210, a small molecule inhibitor of the HDAC family of enzymes.

– Werewolf Therapeutics Inc ($NASDAQ:HOWL)

Werewolf Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies. The company’s lead product candidate, WTX-124, is a monoclonal antibody that targets the protein CD47, which is overexpressed on the surface of cancer cells and inhibits the body’s natural immune response to cancer. Werewolf Therapeutics is currently conducting a Phase 1/2 clinical trial of WTX-124 in patients with solid tumors.

The company’s market cap as of 2022 is 112.8M. The company has a Return on Equity of -28.8%.

Summary

TSCAN Therapeutics is an oncology-focused biopharmaceutical company developing a novel class of treatments for cancer. The company’s TCR-T technologies are based on the discovery of T cell receptors (TCRs) and use these receptors to target tumor-specific antigens in patients’ own immune systems. With two 2024 TCR-T data readouts, investors may stand to gain significant value from the company’s progress. The clinical data from two pivotal Phase 3 trials of TCR-T is expected to provide key insights into the efficacy of the therapy for patients. Moreover, the success of the trials could lead to FDA approval and market launch of the treatments, unlocking a lucrative new market for the company.

Additionally, TSCAN also has a pipeline of other treatments with potential commercialization, potentially providing further value in the future.